Table of Contents
1. Hemophilia A Treatment Market Summary
2. Hemophilia A Treatment Overview
2.1. Disease Definition
2.2. Hemophilia Types
2.2.1. Mild
2.2.2. Moderate
2.2.3. Severe
2.3. Disease Symptoms
3. Current Diagnosis Patterns
4. Treatment Patterns of Hemophilia A
4.1. Treatment Guidelines for Hemophilia A
5. Hemophilia A treatment Epidemiology -Prevalent Population & Segmentations
5.1. Prevalent Population Globally (2016-2022)
5.1.1. Mild Prevalent Cases (2016-2022)
5.1.2. Moderate Prevalent Cases (2016-2022)
5.1.3. Severe Prevalent Cases (2016-2022)
5.2. Prevalent Population in the United States (2016-2022)
5.2.1. Mild Prevalent Cases (2016-2022)
5.2.2. Moderate Prevalent Cases (2016-2022)
5.2.3. Severe Prevalent Cases (2016-2022)
5.3. Prevalent Population in Germany (2016-2022)
5.3.1. Mild Prevalent Cases (2016-2022)
5.3.2. Moderate Prevalent Cases (2016-2022)
5.3.3. Severe Prevalent Cases (2016-2022)
5.4. Prevalent Population in France (2016-2022)
5.4.1. Mild Prevalent Cases (2016-2022)
5.4.2. Moderate Prevalent Cases (2016-2022)
5.4.3. Severe Prevalent Cases (2016-2022)
5.5. Prevalent Population in Italy (2016-2022)
5.5.1. Mild Prevalent Cases (2016-2022)
5.5.2. Moderate Prevalent Cases (2016-2022)
5.5.3. Severe Prevalent Cases (2016-2022)
5.6. Prevalent Population in Spain (2016-2022)
5.6.1. Mild Prevalent Cases (2016-2022)
5.6.2. Moderate Prevalent Cases (2016-2022)
5.6.3. Severe Prevalent Cases (2016-2022)
5.7. Prevalent Population in United Kingdom (2016-2022)
5.7.1. Mild Prevalent Cases (2016-2022)
5.7.2. Moderate Prevalent Cases (2016-2022)
5.7.3. Severe Prevalent Cases (2016-2022)
5.8. Prevalent Population in Japan (2016-2022)
5.8.1. Mild Prevalent Cases (2016-2022)
5.8.2. Moderate Prevalent Cases (2016-2022)
5.8.3. Severe Prevalent Cases (2016-2022)
6. Current and Future Approaches of Care in Hemophilia A Treatment
6.1. Pre-replacement Therapy
6.2. Replacement Therapy
6.2.1. On Demand
6.2.2. Prophylaxis
6.3. Non-Replacement Therapy
6.3.1. Mimetics/Agonists
6.4. Gene Therapy
7. Marketed Drugs & Sales Forecast in Hemophilia A Treatment
7.1. CSL Behring: Afstyla (Antihemophilic Factor (Recombinant), Single Chain)
7.1.1. Product Profile
7.1.2. Safety & Efficacy
7.1.3. Afstyla Sales Forecast-2016-2022
7.2. Biogen IDEC: Eloctate [Antihemophilic Factor (Recombinant), Fc Fusion Protein]
7.2.1. Product Profile
7.2.2. Safety & Efficacy
7.2.3. Eloctate Sales Forecast-2016-2022
7.3. Genentech: Hemlibra (emicizumab-kxwh)
7.3.1. Product Profile
7.3.2. Safety & Efficacy
7.3.3. Hemlibra Sales Forecast-2016-2022
7.4. Bayer: Kogenate FS (Antihemophilic Factor Recombinant)
7.4.1. Product Profile
7.4.2. Safety & Efficacy
7.4.3. Kogenate FS Sales Forecast-2016-2022
7.5. Bayer: Kovaltry [Antihemophilic Factor (Recombinant)
7.5.1. Product Profile
7.5.2. Safety & Efficacy
7.5.3. Kovaltry Sales Forecast-2016-2022
7.6. Octapharma: Nuwiq (recombinant Factor VIII)
7.6.1. Product Profile
7.6.2. Safety & Efficacy
7.6.3. Nuwiq Sales Forecast-2016-2022
7.7. Shire (Baxter): Obizur [Antihemophilic Factor (Recombinant), Porcine Sequence]
7.7.1. Product Profile
7.7.2. Safety & Efficacy
7.7.3. Obizur Sales Forecast-2016-2022
8. Market Size & Forecast of Hemophilia A Treatment(2016-2022)
8.1. Market Forecast by Disease Care
8.1.1. Prophylaxis-Market Forecast (2016-2022)
8.1.2. On-demand therapy-Market Forecast (2016-2022)
8.1.3. Inhibitor therapy- Market Forecast (2016-2022)
8.2. Market Forecast by G7 Countries (2016-2022)
8.2.1. United States- Market Forecast (2016-2022)
8.2.2. Germany- Market Forecast (2016-2022)
8.2.3. France-Market Forecast (2016-2022)
8.2.4. Italy- Market Forecast (2016-2022)
8.2.5. Spain- Market Forecast (2016-2022)
8.2.6. United Kingdom- Market Forecast (2016-2022)
8.2.7. Japan- Market Forecast (2016-2022)
9. Factors Driving the Market of Hemophilia A Treatment
10. Factors Restraining the Market of Hemophilia A Treatment
11. About Polaris Market Research
12. Disclaimer
13. Sales Support